large B-cell lymphoma
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:0081452
Name large B-cell lymphoma
Definition A B-cell lymphoma that is characterized by large lymphoid cells of the B-cell lineage that by definition form sheets or clusters.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma large B-cell lymphoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Active, not recruiting USA 0
NCT03960840 Phase I Ibrutinib + YTB323 YTB323 CD19-specific CAR-T Cells in CLL/SLL and DLBCL Active, not recruiting USA | ITA | FRA | ESP | DEU | AUT | AUS 1
NCT04002947 Phase II Acalabrutinib + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma Recruiting USA 0
NCT04231877 Phase I Cyclophosphamide + Doxorubicin + Etoposide + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisone + Rituximab Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma Recruiting USA 0
NCT04970901 Phase I Obinutuzumab Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb Loncastuximab tesirine-lpyl + Polatuzumab vedotin-piiq Glofitamab-gxbm + Loncastuximab tesirine-lpyl A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) Recruiting USA | ITA | GBR | ESP | CZE | BEL 0
NCT05412290 Phase I Mosunetuzumab-axgb Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma Recruiting USA 0
NCT05421663 Phase Ib/II C-CAR039 A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma Recruiting USA | NLD | GBR | ESP | DNK | CAN | AUS 1
NCT05852717 Phase II Cisplatin + Dexamethasone + Epcoritamab-bysp + Gemcitabine Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma Recruiting USA 0
NCT06045910 Phase Ib/II ALETA-001 A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies Recruiting GBR 0
NCT06050694 Phase II Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) (GRAIL) Recruiting CAN 0
NCT06071871 Phase II Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma (PORTAL) Recruiting GBR 0
NCT06167785 Phase II Zanubrutinib Tislelizumab + Zanubrutinib Tislelizumab A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T (ZeTA) Recruiting CAN 0
NCT06248086 Phase I ASP101G + ASP2802 A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas Terminated AUS 0
NCT06340737 Phase I Anti-CD22 CAR T cells AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas Recruiting USA 0
NCT06414148 Phase II Epcoritamab-bysp + Lenalidomide + Rituximab Epcoritamab-bysp MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART) Recruiting AUS 0
NCT06486051 Phase II Cyclophosphamide + Fludarabine WZTL-002 A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma (ENABLE-2) Recruiting NZL 0
NCT06500273 Phase II ALLO-501A Cyclophosphamide + Fludarabine Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (ALPHA3) Recruiting USA | CAN 0
NCT06526793 Phase II TNB-486 AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL (SOUNDTRACK-B) Recruiting USA | SWE | ITA | GBR | FRA | ESP | DNK | DEU | CAN | BRA | AUS 5
NCT06528301 Phase I UB-VV111 Sirolimus + UB-VV111 A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies Recruiting USA | AUS 0
NCT06536049 Phase Ib/II Epcoritamab-bysp + Ibrutinib Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT06542250 Phase Ib/II AZD5492 A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. (TITANium) Recruiting USA | ITA | FRA | ESP | DNK | DEU | CAN | AUS 2
NCT06564038 Phase Ib/II Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + TNB-486 + Vincristine Sulfate Acalabrutinib + TNB-486 TNB-486 A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (Soundtrack-E) Recruiting USA | ITA | GBR | FRA | ESP | DNK | DEU | CZE | AUS 4
NCT06593145 Phase I Tarcidomgen kimleucel CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms (CARLA) Recruiting POL 0
NCT06594939 Phase II Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Prednisone Pegfilgrastim Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Prednisone Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma Not yet recruiting USA 0
NCT06723457 Phase II Epcoritamab-bysp + Lenalidomide Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma Recruiting USA 0
NCT06730542 Phase I Cyclophosphamide + Doxorubicin + Methotrexate + Polatuzumab vedotin-piiq + Prednisone + Rituximab + Zanubrutinib Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in Patients with Secondary CNS Lymphoma Recruiting USA 0
NCT06760156 Phase II Lenalidomide + Tafasitamab-cxix Phase 2 Study of Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym Recruiting USA 0
NCT06784726 Phase II Odronextamab Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Recruiting USA 0
NCT06811272 Phase II Epcoritamab-bysp Dexamethasone + Epcoritamab-bysp Outpatient Epcoritamab As 2L in NTE R/R DLBCL Recruiting USA 0
NCT06834373 Phase II CC-99282 + Rituximab Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy Recruiting USA 0
NCT06870487 Phase I PF-08046032 PF-06801591 + PF-08046032 A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers Active, not recruiting USA | ESP 0
NCT06905509 Phase II Cytarabine + Dexamethasone + Epcoritamab-bysp + Oxaliplatin + Rituximab Epcoritamab-bysp + Gemcitabine + Oxaliplatin Carboplatin + Cytarabine + Dexamethasone + Epcoritamab-bysp + Rituximab Carboplatin + Epcoritamab-bysp + Etoposide + Ifosfamide + Rituximab Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Recruiting USA 0
NCT06919939 Phase II Epcoritamab-bysp + Loncastuximab tesirine-lpyl Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma (EPCOR+LONCA) Not yet recruiting USA 0
NCT07052305 Phase I NT-I7 NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Yescarta (Axicabtagene Ciloleucel) or Post-Breyanzi (Lisocabtagene Maraleucel) in Subjects With Relapsed/Refractory Large B-cell Lymphoma Not yet recruiting USA 0
NCT07097363 Phase II Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Etoposide + Prednisone + Rituximab Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Not yet recruiting USA 0
NCT07098364 Phase Ib/II Lisocabtagene maraleucel + ST-067 ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Recruiting USA 0
NCT07108868 Phase I MB-CART2219.1 A Phase I Dose Finding Study of MB-CART2219.1 Recruiting DEU 0
NCT07123454 Phase Ib/II AZD4512 A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (Lumi-NHL) Recruiting USA | ITA | GBR | AUS 3
NCT07126236 Phase II Epcoritamab-bysp Epcoritamab-bysp + Lenalidomide + Tafasitamab-cxix Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma (REPIFIR) Recruiting ESP 0
NCT07215585 Phase III Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + TNB-486 + Vincristine Sulfate AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (SOUNDTRACK-D2) Recruiting TUR | POL | GBR | CAN | BRA | BEL | AUS 4
NCT07226843 Phase I LY4584180 + Rituximab LY4584180 A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers Not yet recruiting USA 0